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Abstract 
11-Hydroxythromboxane B, dehydrogenase purified from porcine kidney has been identified as cytosolic aldehyde dehydrogenase (EC 1.2.1.3). 
This identification is based on protein characteristics, equence analysis of one proteolytic digest, blocked N-terminus, subunit molecular mass of 
55 kDa, and enzymatic activities. The sequence difference with the human enzyme is 7.5% in the fragments analyzed (29 exchanges of 388 positions, 
corresponding to the expected species variability for cytosolic aldehyde dehydrogenase). The substrate thromboxane B, contains a hernia&al in its 
ring structure, but the reaction most likely proceeds via the aldehyde form of the substrate. This finding is in agreement with the proposed metabolism 
of 4-hydroxycyclophosphamide and highlights the possibility that molecules containing a hemiacetal structure can function as substrates for aldehyde 
dehydrogenase. 
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1. rntroductioIl 
Eicosanoids encompass everal groups of compounds: 
prostaglandins, thromboxanes, leukotrienes and lipox- 
ins. Several of these substances are metabolized via dehy- 
drogenase catalyzed reactions [l-3]. The most studied 
enzyme is the 15-hydroxyprostaglandin dehydrogenase 
from human placenta which is responsible for the inacti- 
vation of prostaglandins [2,3]. This enzyme has been 
found to belong to the short-chain alcohol dehydroge- 
nase family [4,5]. 
The metabolic fate of thromboxane A,, a potent plate- 
let aggregator and vasoconstrictor, is nonenzymatic de- 
composition to the biologically inactive thromboxane B2 
(TXB,) (Fig. 1). TXB2 is further metabolized by two 
major pathways, one is B-oxidation from the carboxyl 
end, and the other reduction of carbon atom 11 through 
a dehydrogenase catalyzed reaction [3,6]. These two 
pathways lead to the major metabolites, ll-dehydro- 
TXB2, 2,3-dinor-l l-dehydro-TXB, and 2,3-dinor-TXB, 
(Fig. l), which are excreted in human urine [6-lo]. The 
major metabolite in the human circulation is ll-dehy- 
dro-TXB, [7,11]. The metabolites are used to quantify 
thromboxane production during different physiological 
and pathological events, such as heart attack, and one of 
the major treatment strategies in diseases with throm- 
boembolic pathology is to inhibit platelet thromboxane 
synthesis with aspirin [12-151. 
We have recently puritied the 1 l-hydroxythrom- 
boxane B2 dehydrogenase from porcine kidney [16]. The 
enzyme was found to have a subunit with a molecular 
*Corresponding author. Fax: (46) (8) 729 3485. 
mass of 55 kDa. The catalytic activity was dependent on 
NAD+, showed irreversibility, and prostaglandins were 
not substrates for the enzyme. In the present work we 
have characterized the 1 I-hydroxy-thromboxane B2 de- 
hydrogenase, and identify it as cytosolic aldehyde dehy- 
drogenase. 
2. Materials and methods 
2.1. Il-Hydroxythromboxane B2 dehydrogenase 
The enzyme was purified from porcine kidney as described [16] using 
ammonium sulphate precipitation of the proteins in the 100,000 x g 
supernatant, ion exchange chromatography (DE-52, Whatman), afIin- 
ity chromatography (5’-AMP-Sepharose, Pharmacia) and gel permea- 
tion chromatography (Protein Pak 125, Waters). The purity was con- 
trolled by SDS/polyacrylamide gel electrophoresis, using the Phast 
(Phannacia) or Mini Protean II (Bio-Rad) systems. The purity was 
better than 95%. 
The enzyme was tested for catalytic activity with 1 mM NAD’ 
(Sigma) and 1 mM of [l-i4C]TXB, in 250 mM Tris-HCl, pH 8.0,37’C. 
The labelled TXB, was obtained by incubation of [l-‘4C@rachidonic 
acid (Amersham) with human washed platelets, and was diluted to the 
proper specific activity with synthetic TXB2 (Cayman Chemical) [16]. 
Analysis of the enzymatic activity was performed by TLC in combina- 
tion with autoradiography and scintillation counting [16]. 
2.2. Structural analysis 
The protein was reduced with dithiothreitol and carboxymethylated 
with ‘%-labeled iodoacetate (Amersham) [17]. The radiolabeled en- 
zyme was treated with a Lys-specific protease from Achromobactor 
(Vaco) for 4 h in 0.1 M ammonium bicarbonate, pH 8.0, 37°C. The 
digest was separated by reverse phase HPLC (Waters), applying a linear 
gradient of &60% acetonitrile in 0.1% aqueous trifluoroacetic acid for 
90 min, using a C, column (5 pm, 250 x 4 mm, Vydac). The flow rate 
was 1 mlmin-‘l and UV absorption was recorded at 214 and 280 nm. 
Sequence degradations were carried out with ABl 470A and 447A 
sequencers (Applied Biosystems). Total compositions of the enzyme 
were determined with a Phannacia Alpha Plus analyzer after hydrolysis 
in evacuated tubes with 6 M HCl, 0.5% phenol for 24 h at 110°C. 
Tryptophan was determined after hydrolysis with 4 M methane 
sulphonic acid for 20 h at 110°C. 
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3. Results 
11 -Hydroxythromboxane BZ dehydrogenase was pu- 
rified from porcine kidney [16]. The enzyme obtained 
was pure as revealed by SDS/polyacrylamide gel electro- 
phoresis and corresponded to a subunit molecular mass 
of 55 kDa. Determination of the molecular mass of the 
native enzyme was complicated by the fact that the en- 
zyme lost activity in the affinity chromatography on S- 
AMP-Sepharose; the final purification step, gel permea- 
tion, has previously been interpreted to suggest hat the 
enzyme may dissociate under loss of activity (cf. [16]). 
The pure enzyme obtained was 14C-carboxymethyl- 
ated and submitted to structural analysis; Attempts at 
direct sequence analysis did not produce any results, 
showing that the N-terminus is blocked. Cleavage with 
a Lys-specific protease and subsequent peptide separa- 
tions by HPLC produced peptides suitable for analysis 
and 35 peptide sequences were determined in 24 different 
fractions (Fig. 2) accounting for a total of 388 residues. 
These results identify the 11 -hydroxythromboxane B, 
dehydrogenase as identical to cytosolic aldehyde dehy- 
drogenase, with a residue identity of 92.5% between the 
porcine protein and human cytosolic aldehyde dehydro- 
genase [14. Furthermore, total compositions are similar 
(Table l), the present N-terminus is blocked like that of 
cytosolic aldehyde dehydrogenase (acetylated, cf. [ 17]), 
and subunit molecular masses are identical, around 55 
kDa by SDS/polyacrylamide gel electrophoresis for the 
present enzyme vs. 54.8 kDa for the human enzyme [ 181. 
Hence, although a few segments were not determined, 
compatible with the fact that a single digest was analyzed 
(Fig. 2), it can be safely concluded that porcine 1 l-hy- 
droxythromboxane B2 dehydrogenase corresponds to 
full-length cytosolic aldehyde dehydrogenase with a spe- 
cies variability of about 7.5% vs. the corresponding 
human enzyme. This value is smaller than the horse/ 
human variability (9% cf. [19]) for this enzyme, thus 
further strengthening the argument of ll-hydroxy- 
thromboxane Bz dehydrogenase and cytosolic aldehyde 
dehydrogenase as identical. 
The cysteine at position 302, believed to be the cata- 
lytic centre, is conserved as expected. The amino acid 
substitutions compared to the human enzyme are evenly 
distributed (Table 2) except within the region 160-280 
which showed relatively few positional differences. Only 
one exchange of those established (Table 2) requires a 
2-base difference (Met/Asn at position 120). 
The identification of 1 I-hydroxythromboxane Bz de- 
hydrogenase as cytosolic aldehyde dehydrogenase is a 
novel finding, revealing molecular properties of the little- 
studied 1 1-hydroxythromboxane Bz dehydrogenase and 
adding a further functional role to the more well-studied 
aldehyde dehydrogenase. The identity is also proven by 
OH 
Thromboxane A* (TX.42) 
_cOOH bxidation 
1 I-dehydm TX.& 
‘2.3~dinor- I-dehydro TXBz 
Fig. 1. Major metabolic pathways for thromboxanes. Thromboxane A, (TXAJ decomposes tothromboxane B, (TXBd which is further metabolized 
via B-oxidation and/or dehydrogenation. Whether the metabolite 2,3-dinor-l l-dehydro-TXB, is formed via the two possible pathways or only one 
of them is not known. 
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enzymatic properties. Thus, the 1 l-hydroxythrom- 
boxane Bz dehydrogenase preparation had an enzymatic 
activity for acetaldehyde and propanal typical of cy- 
tosolic aldehyde dehydrogenase. Furthermore, TXBz is 
really a hemiacetal, and upon ring opening gives rise to 
an aldehyde (Fig. 3) which is likely to constitute the true 
substrate for the enzyme (cf. section 4). 
4. Discussion 
This study identifies the 1 I-hydroxythromboxane B2 
dehydrogenase as identical to cytosolic aldehyde dehy- 
drogenase, clarifying the mechanism of the 1 l-hydroxy- 
thromboxane B, dehydrogenase and proving additional 
important functions for the aldehyde dehydrogenase. 
Three points are of special interest and constitute impor- 
tant facts for further investigations. 
4.1. Catalytic mechanism 
The catalytic mechanism for the conversion of TXB2 
to 1 I-dehydro-TXB, by aldehyde dehydrogenase is 
probably explained by the hemiacetal structure formed 
between carbon atom 11 and 12 in the ring system of 
TXB2 (Fig. 3). TXB, can exist in three forms, two anom- 
ers with the 11-hydroxyl group in d or j&position, and 
the aldo form with an open ring structure. The aldo form 
of TXB, is the most likely substrate candidate. There are 
only a few studies dealing with the conformation of 
TXB, in different solutions. However, it is dependent on 
the solvent. Kotovych and Aarts [20] reported 76% 1 la- 
OH TXBz and 24% 1 l/?-OH TXB, in CDCl,. However, 
in CD30D the predominant anomer was 1 l/?-OH (80%). 
The same authors did not report any aldehyde form of 
the molecule. However, it is a continuous equilibrium 
between the two forms [21]. The relatively high &, and 
low V_ values for TXB, (cf. [16]), most likely depends 
on the fact that only a small portion of the substrate 
exists in the aldo form. 
4-Hydroxycyclophosphamide, the metabolite of cyclo- 
phosphamide, has also been shown to be a substrate for 
aldehyde dehydrogenase; for review see [22]. The struc- 
ture of 4-hydroxycyclophosphamide resembles that of 
TXB2, with three possible conformations. In this case the 
aldo form, aldophosphamide, is regarded as the sub- 
strate for aldehyde dehydrogenase [22], further support- 
ing the aldo form of TXB, as the suitable substrate for 
aldehyde dehydrogenase. 
Another similarity exists between the metabolism of 
4-hydroxycyclophosphamide and TXB2. After dehydro- 
genation the product can exist in two interconvertable 
conformations, an acyclic form and a Slactone or S- 
lactam. This has clearly been demonstrated for 1 l-dehy- 
dro-TXB, with a preference for the S-lactone at acidic 
pH and the open ring form at basic pH (Fig. 1) [23]. 
A similar interconversion between carboxyphospha- 
mide and 4-ketocyclophosphamide is not believed to 
take place, although this has not been studied in detail 
P21. 
Our findings together with the metabolic data earlier 
reported for 4-hydroxycyclophosphamide highlight a 
novel group of substrates for aldehyde dehydrogenase, 
although not previously recognized from the conforma- 
tion of the substrate, hemiacetal, or of the product, S- 
lactone (Figs. 1 and 3). 
4.2. Metabolic interaction 
The identification of 1 1-hydroxythromboxane B2 de- 
hydrogenase as cytosolic aldehyde dehydrogenase fitr- 
ther stresses the importance of measurements of meta- 
bolites from the two pathways (Fig. 1) when estimating 
thromboxane biosynthesis in vivo, since several en- 
dogenous and exogenous (cf. above) compounds might 
interfere with the dehydrogenase-catalyzed reaction and 
thus influence the recorded urinary and blood levels of 
both 1 1-dehydro-TXB, and 2,3-dinor-TXB,. Relying on 
only one parameter might lead to a false interpretation 
of the data. Thus, measurements of an increase or de- 
crease of one metabolite might reflect altered metabolism 
and not a change in the biosynthesis of the biologically 
important compound, TXA, (Fig. 1). 
In in vitro studies the organ distribution and propor- 
Table 1 
Total composition of 11-hydroxythromboxane B, dehydrogenase after 
acid hydrolysis of the carboxymethylated porcine enzyme 
Amino acid 1 1-Hydroxythromboxane Bz Cytosolic aldehyde 
dehydrogenase (porcine) dehydrogenase (human) 
(moYmo1) (mol/mol) 
CYS (Cm) 9.4 11 
Asx 45.9 46 
Thr 25.9 28 
Ser 30.8 29 
Glx 51.9 50 
Pro 27.2 24 
Gly 49.1 48 
Ala 40.3 38 
Val 34.3 38 
Met 11.4 8 
Ile 32.1 35 
Lell 39.8 37 
Tyr 14.2 16 
Phe 23.4 22 
Trp 5.4 I 
I-YS 38.6 38 
His 8.8 8 
‘% 16.2 17 
SUIII 500 
Values are from acid hydrolysis with 6 M HCl/0.5% phenol for 24 h at 
llO”C, and for tryptophan, hydrolysis with 4 M methane sulphonic 
acid for 20 h at 110°C; all values without corrections for destruction, 
incomplete release or impurities. For comparison, the total composi- 
tion of human liver cytosolic aldehyde dehydrogenase is also given 
(from sum of amino acid sequence [lq). 
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Fig. 2. HPLC chromatogram from the purification of the peptides obtained after digestion of 1 I-hydroxy-thromboxane B2 dehydrogenase with a 
Lys-specitic protease. The start and stop positions in the aldehyde dehydrogenase structure [17] of all peptides analyzed from each fraction are 
indicated by the numbers. 
tion of the different metabolizing systems, /I-oxidation kidney, stomach, liver, aorta, spleen and heart, whereas 
and 11 -hydroxy-dehydrogenation, are of importance for the brain showed no detectable activity. Although the 
the recorded levels of the metabolites. The organ distri- distribution of cytosolic aldehyde dehydrogenase often 
bution of 11 -hydroxythromboxane Bz dehydrogenase is regarded as predominating in liver, it also has an over- 
has only been reported for one species [24]. In the rabbit, all similar distribution. Noticeably, the organ distribu- 
the lung showed the highest activity followed by the tion of alcohol dehydrogenase class I [25], which in gen- 
Table 2 
Sum of established positional differences between 1 I-hydroxythromboxane B, dehydrogenase now analyzed and cytosolic aldehyde dehydrogenase 
previously known, corresponding to species variants between porcine and human forms of 11-hydroxytromboxane B, dehydrogenase/cytosolic 
aldehyde dehydrogenase 
Position Porcine Human Position Porcine Human 
17 Phe 
47 LYS 
50 Glu 
86 Gln 
89 Asn 
114 Phe 
120 Met 
123 Gly 
127 Arg 
140 His 
146 Met 
156 Ser 
238 Val 
248 Gln 
278 Phe 
Ile 
Glu 
Gin 
Arg 
Tyr 
Tyr 
Asn 
Ala 
LYS 
Ghl 
Ile 
His 
Ile 
Glu 
L-3 
285 Ala 
294 Leu 
308 LeU 
316 Asn 
330 Val 
340 Asn 
351 Glu 
381 Ile 
424 Tyr 
442 Val 
448 Ser 
459 LeU 
462 His 
482 JL-SU 
Asn 
Val 
Ile 
ASP 
Ile 
Thr 
Asp 
Val 
Phe 
Ile 
Ala 
Val 
Ghl 
Phe 
Differences hown are those established after analysis of 388 positions, covering the following positions of the human enzyme : 17-27,36-61,65-90, 
113-202, 210-251 (235 and 239 incompletely confumed), 26316, 328-361, 367-409,412-425 and 439-487. 
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Fig. 3. Conformations of thromboxane BP Because of the hemiacetal 
structure within the ring of TKBl the molecule can exist in three differ- 
ent forms, the 11-a and 11-/J anomers, and the aldo form. It is a 
continuous equilibrium between the different forms and the propor- 
tions of the isomers are dependent on the solvent [20,21]. 
era1 is believed to follow the distribution of cytosolic 
aldehyde dehydrogenase, shows a pattern similar to that 
of 1 1-hydroxy-thromboxane B2 dehydrogenase. 
4.3. Enzyme structure 
The cytosolic aldehyde dehydrogenase from liver of 
different species are all tetramers and an N-terminal seg- 
ment has been suggested to play a role in subunit interac- 
tion [26]. 
The enzyme described in the present paper was previ- 
ously regarded as a monomer, based on behaviour upon 
gel permeation chromatography. However, the chroma- 
tography was also dependent on ionic interactions which 
influenced the results [16]. The present identification 
therefore supports the notion that native ll-hydroxy- 
thromboxane Bz dehydrogenase may be tetrameric, like 
aldehyde dehydrogenase, and that the quaternary struc- 
ture is influenced by environmental interactions [16]. 
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